Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Traina, Fabiola ^a,b   Visconte, Valeria ^a   Jankowska, Anna M ^a   Makishima, Hideki ^a   O'Keefe, Christine L ^a   Elson, Paul ^c   Han, Yingchun ^c   Hsieh, Fred H ^c   Sekeres, Mikkael A ^a   Mali, Raghuveer Singh ^d   Kalaycio, Matt ^a   Lichtin, Alan E ^a   Advani, Anjali S ^a   Duong, Hien K ^a   Copelan, Edward ^a   Kapur, Reuben ^d   Olalla Saad, Sara T ^b   Maciejewski, Jaroslaw P ^a   Tiu, Ramon V ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; CD2 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ADOLESCENT; ADULT; AGED; AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ARTICLE; ASXL1 GENE; BONE MARROW BIOPSY; CBL GENE; CHILD; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 2P; CHROMOSOME 4Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNMT3A GENE; EZH2 GENE; FEASIBILITY STUDY; FEMALE; FRAMESHIFT MUTATION; GENE; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; INDOLENT SYSTEMIC MASTOCYTOSIS; KARYOTYPING; KIT GENE; MALE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NONSENSE MUTATION; OVERALL SURVIVAL; PROGNOSIS; SARCOMA; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC MASTOCYTOSIS; TET2 GENE; THROMBOCYTE COUNT; UNIPARENTAL DISOMY; X CHROMOSOME;

ADOLESCENT; ADULT; AGED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KARYOTYPING; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; REPRESSOR PROTEINS;

EID: 84865062086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043090     Document Type: Article

References (34)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, et al. ((2001)) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25:: 603--625.
2. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, et al. ((2007)) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:: 435--453.
3. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, et al. ((1999)) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94:: 2333--2342.
4. Tefferi A, Pardanani A, ((2004)) Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11:: 58--64.
5. Horny HP, Metcalfe DD, Bennett BD, Bain BJ, Akin C, et al. (2008) Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 54-63.
6. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, et al. ((1995)) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:: 10560--10564.
7. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C, ((2002)) Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 100:: 661--665.
8. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, et al. ((2003)) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 22:: 660--664.
9. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, et al. ((2006)) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:: 2366--2372.
10. Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, et al. ((2004)) On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 34 (Suppl 2):: 41--52.
11. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, et al. ((2009)) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113:: 6403--6410.
12. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, et al. ((2009)) Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 27:: 6109--6116.
13. Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, et al. ((2010)) Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 49:: 390--399.
14. Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, et al. ((2010)) Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24:: 1799--1804.
15. Tefferi A, ((2010)) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:: 1128--1138.
16. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, et al. ((2010)) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:: 2424--2433.
17. Walter MJ, Ding L, Shen D, Shao J, Grillot M, et al. ((2011)) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:: 1153--1158.
18. Tiu R, Gondek L, O'Keefe C, Maciejewski JP, ((2007)) Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 21:: 1648--1657.
19. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, et al. ((2008)) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:: 1534--1542.
20. Green A, Beer P, ((2010)) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362:: 369--370.
21. Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, et al. ((2010)) Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. Br J Haematol 150:: 83--87.
22. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, et al. ((2011)) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:: 2496--2506.
23. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL, ((2010)) The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 24:: 1656--1657.
24. Horny HP, Valent P, ((2001)) Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25:: 543--551.
25. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, et al. ((2009)) Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23:: 900--904.
26. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. ((2009)) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:: 739--744.
27. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. ((2010)) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:: 553--567.
28. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, et al. ((2010)) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:: 339--344.
29. Wang J, Hevi S, Kurash JK, Lei H, Gay F, et al. ((2009)) The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41:: 125--129.
30. Lee SW, Cho YS, Na JM, Park UH, Kang M, et al. ((2010)) ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 285:: 18--29.
31. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, et al. ((2011)) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:: 3932--3941.
32. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, et al. ((2010)) ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 151:: 365--375.
33. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, et al. ((2003)) Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27:: 739--742.
34. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, et al. ((2000)) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 28:: 140--147.